原发肺肿瘤手术切除顺序对寡转移非小细胞肺癌的影响
本研究纳入2005至2017年同步寡转移IV期非小细胞肺癌患者,比较先期肺切除与先期全身治疗的结局。两组围术期并发症、住院时间、疾病进展比例、总死亡、中位无进展生存期与总生存期均无显著差异。单器官转移者无进展生存期与总生存期显著优于寡转移者,非孤立转移是无进展生存期的唯一独立预测因子。
要点
- 先期肺切除与先期全身治疗在围术期并发症及生存结局上无显著差异。
- 单器官转移患者无进展生存期与总生存期显著优于寡转移患者。
- 非孤立转移是无进展生存期的唯一独立预测因子。
核心结论
- 在诱导全身治疗前或后行原发肺切除可能使寡转移非小细胞肺癌患者获益。
- 建议未来开展随机临床试验评估治疗顺序的影响。
研究设计与样本
- 回顾性队列研究,纳入2005至2017年同步寡转移IV期非小细胞肺癌患者。
- 共51例患者接受肿瘤切除,其中33例(64.7%)先手术、18例(35.3%)先全身治疗。
主要发现
- 先手术组患者年龄更大(62.1 vs 54岁),胸腔内分期更早(18% vs 44%)。
- 两组围术期并发症(30% vs 28%)、住院时间(9.0 vs 10.5天)、疾病进展比例(91% vs 94%)、总死亡(70% vs 78%)无显著差异。
- 两组中位无进展生存期(14.0 vs 22.8个月)与总生存期(44.6 vs 53.2个月)无显著差异。
- 单器官转移者无进展生存期(17.5 vs 12.8个月,P = .040)与总生存期(55.6 vs 39.8个月,P = .035)显著优于寡转移者。
- 多变量Cox分析显示非孤立转移是无进展生存期的唯一独立预测因子(风险比2.27,95%置信区间1.07-4.81,P = .033)。
临床怎么用
- 原发肺切除可在全身治疗前或后进行,两者围术期安全性与生存结局相近。
- 单器官转移患者可能从原发肺切除中获得更长的无进展生存期与总生存期。
局限性
- 回顾性研究设计,样本量有限(51例接受切除)。
- 两组基线特征存在差异(年龄、胸腔内分期)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Differing surgical series for the treatment of primary lung tumor with synchronous oligometastatic stage IV non-small cell lung cancer (NSCLC) have been published; however, outcomes remain ambiguous. METHODS: Patients with synchronous oligometastatic stage IV NSCLC treated from 2005 to 2017 were enrolled to identify the impact of treatment sequence (primary lung resection vs systemic treatment) on progression-free survival (PFS) and overall survival (OS). RESULTS: Tumor resection occurred in 51 patients (84% adenocarcinoma, 55% nonsmokers, and 65% driver gene mutation) before or after systemic treatment in 33 (64.7%) and 18 (35.3%) patients, respectively. Patients who received resection first were older (62.1 vs 54 years) and at a less advanced intrathoracic stage (18% vs 44%). No significant differences were noted regarding perioperative complications (30% vs 28%), hospital length of stay (9.0 vs 10.5 days), percentage of disease progression (91% vs 94%), overall death (70% vs 78%), median PFS (14.0 vs 22.8 months), and OS (44.6 vs 53.2 months). Patients with single-organ metastasis had significantly longer PFS and OS than those with oligometastases (17.5 vs 12.8 months, P = .040; and 55.6 vs 39.8 months, P = .035), respectively. Multivariable Cox analysis identified nonsolitary metastasis as the only independent predictor of PFS (hazard ratio, 2.27; 95% confidence interval, 1.07-4.81; P = .033). CONCLUSIONS: Primary lung resection before or after induction systemic therapy may benefit patients with oligometastatic NSCLC. Future randomized clinical trials examining the effect of treatment sequence is recommended.
引用
- Shyr BS, Huang CS, Chen HS, et al. Sequence for Surgical Resection of Primary Lung Tumor for Oligometastatic Non-small Cell Lung Cancer. Ann Thorac Surg. 2021. PMID: 33964254. doi:10.1016/j.athoracsur.2021.04.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。